Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response

dc.contributor.author	Llamoza-Torres, Camilo-Julio
dc.contributor.author	Fuentes-Pardo, María
dc.contributor.author	Ramos-Molina, Bruno
dc.date.accessioned	2025-11-20T12:50:18Z
dc.date.available	2025-11-20T12:50:18Z
dc.date.issued	2024-12
dc.identifier.citation	Llamoza-Torres CJ, Fuentes-Pardo M, Ramos-Molina B. Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response. Metab Target Organ Damage [Internet]. 13 de noviembre de 2024 [citado 20 de noviembre de 2025];4(4). Disponible en: https://www.oaepublish.com/articles/mtod.2024.64
dc.identifier.uri	https://sms.carm.es/ricsmur/handle/123456789/21797
dc.language.iso	eng
dc.publisher	OAE PUBLISHING INC
dc.rights	Atribución-NoComercial-SinDerivadas 3.0 España
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/3.0/es/	*
dc.title	Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response
dc.type	info:eu-repo/semantics/article
dc.relation.publisherversion	https://www.oaepublish.com/articles/mtod.2024.64
dc.identifier.doi	10.20517/mtod.2024.64
dc.journal.title	Metabolism and Target Organ Damage
dc.identifier.essn	2769-6375